Tavapadon (Juvmo)
To treat Parkinson’s disease in adults
In 304 adults with early Parkinson's disease, flexible-dose tavapadon improved MDS-UPDRS II+III score at 26 weeks vs placebo (LSM −10.3 vs −1.2; difference −9.1). Adverse events 76% vs 55%; discontinuation 38% vs 15%, mostly for adverse events. RCT · phase 3 · n = 304 · Lancet Neurol · 2026
In a phase 3 RCT of 507 adults with Parkinson disease and motor fluctuations on levodopa, tavapadon vs placebo increased daily good-on-time by 1.10 hours at week 26 (P<.001); adverse events were more frequent (71.7% vs 55.1%), mostly mild to moderate. RCT · phase 3 · n = 507 · JAMA Neurol · 2026